Among all the hits, SSX2IP caused our attention, previous studies indicated that SSX2IP is an acute myeloid leukemia-associated antigen and a potential immunotherapy target for leukemia [33]–[35] and our previous work showed that SSX2IP promotes the invasion and migration of hepatocellular carcinoma cells and contributes to the chemotherapy resistance [36]. The gene discussed is SSX2IP; the disease is hepatocellular carcinoma.